375 related articles for article (PubMed ID: 36499591)
1. New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases.
Zhan S; Yung MMH; Siu MKY; Jiao P; Ngan HYS; Chan DW; Chan KKL
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499591
[TBL] [Abstract][Full Text] [Related]
2. SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells.
Xuan Y; Wang H; Yung MM; Chen F; Chan WS; Chan YS; Tsui SK; Ngan HY; Chan KK; Chan DW
Theranostics; 2022; 12(7):3534-3552. PubMed ID: 35547771
[No Abstract] [Full Text] [Related]
3. Adipocyte pyroptosis occurs in omental tumor microenvironment and is associated with chemoresistance of ovarian cancer.
Lin CN; Liang YL; Tsai HF; Wu PY; Huang LY; Lin YH; Kang CY; Yao CL; Shen MR; Hsu KF
J Biomed Sci; 2024 Jun; 31(1):62. PubMed ID: 38862973
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis induction via targeting metabolic alterations in head and neck cancer.
Lee J; Roh JL
Crit Rev Oncol Hematol; 2023 Jan; 181():103887. PubMed ID: 36442748
[TBL] [Abstract][Full Text] [Related]
5. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
Nieman KM; Kenny HA; Penicka CV; Ladanyi A; Buell-Gutbrod R; Zillhardt MR; Romero IL; Carey MS; Mills GB; Hotamisligil GS; Yamada SD; Peter ME; Gwin K; Lengyel E
Nat Med; 2011 Oct; 17(11):1498-503. PubMed ID: 22037646
[TBL] [Abstract][Full Text] [Related]
6. Omentum: Friend or foe in ovarian cancer immunotherapy?
Bella Á; Arrizabalaga L; Di Trani CA; Fernández-Sendin M; Teijeira A; Russo-Cabrera JS; Melero I; Berraondo P; Aranda F
Int Rev Cell Mol Biol; 2022; 371():117-131. PubMed ID: 35964998
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal metastasis of ovarian cancer: new insights on resident macrophages in the peritoneal cavity.
Miyamoto T; Murphy B; Zhang N
Front Immunol; 2023; 14():1104694. PubMed ID: 37180125
[TBL] [Abstract][Full Text] [Related]
8. Omentum-on-a-chip: A multicellular, vascularized microfluidic model of the human peritoneum for the study of ovarian cancer metastases.
Ibrahim LI; Hajal C; Offeddu GS; Gillrie MR; Kamm RD
Biomaterials; 2022 Sep; 288():121728. PubMed ID: 35995621
[TBL] [Abstract][Full Text] [Related]
9. The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.
Ritch SJ; Telleria CM
Front Endocrinol (Lausanne); 2022; 13():886533. PubMed ID: 35574025
[TBL] [Abstract][Full Text] [Related]
10. Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers.
Yung MMH; Siu MKY; Ngan HYS; Chan DW; Chan KKL
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743298
[TBL] [Abstract][Full Text] [Related]
11. Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells.
Chen RR; Yung MMH; Xuan Y; Zhan S; Leung LL; Liang RR; Leung THY; Yang H; Xu D; Sharma R; Chan KKL; Ngu SF; Ngan HYS; Chan DW
Commun Biol; 2019; 2():281. PubMed ID: 31372520
[TBL] [Abstract][Full Text] [Related]
12. Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.
Yeung TL; Leung CS; Yip KP; Au Yeung CL; Wong ST; Mok SC
Am J Physiol Cell Physiol; 2015 Oct; 309(7):C444-56. PubMed ID: 26224579
[TBL] [Abstract][Full Text] [Related]
13. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
[TBL] [Abstract][Full Text] [Related]
14. Revisiting the Use of Normal Saline for Peritoneal Washing in Ovarian Cancer.
Akasaka H; Naora H
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003636
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer.
Kobayashi H; Yoshimoto C; Matsubara S; Shigetomi H; Imanaka S
Cancer Drug Resist; 2023; 6(3):547-566. PubMed ID: 37842240
[TBL] [Abstract][Full Text] [Related]
16. An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
Motohara T; Masuda K; Morotti M; Zheng Y; El-Sahhar S; Chong KY; Wietek N; Alsaadi A; Carrami EM; Hu Z; Artibani M; Gonzalez LS; Katabuchi H; Saya H; Ahmed AA
Oncogene; 2019 Apr; 38(16):2885-2898. PubMed ID: 30568223
[TBL] [Abstract][Full Text] [Related]
17. Adipokine Apelin/APJ Pathway Promotes Peritoneal Dissemination of Ovarian Cancer Cells by Regulating Lipid Metabolism.
Dogra S; Neelakantan D; Patel MM; Griesel B; Olson A; Woo S
Mol Cancer Res; 2021 Sep; 19(9):1534-1545. PubMed ID: 34172534
[TBL] [Abstract][Full Text] [Related]
18. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
[TBL] [Abstract][Full Text] [Related]
19. Detachment from the primary site and suspension in ascites as the initial step in metabolic reprogramming and metastasis to the omentum in ovarian cancer.
Sato M; Kawana K; Adachi K; Fujimoto A; Yoshida M; Nakamura H; Nishida H; Inoue T; Taguchi A; Ogishima J; Eguchi S; Yamashita A; Tomio K; Komatsu A; Wada-Hiraike O; Oda K; Nagamatsu T; Osuga Y; Fujii T
Oncol Lett; 2018 Jan; 15(1):1357-1361. PubMed ID: 29399186
[TBL] [Abstract][Full Text] [Related]
20. An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum.
Wong T; Tedja R; Chehade H; Morris R; Alvero AB; Mor G
J Vis Exp; 2024 Jan; (203):. PubMed ID: 38345216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
